Back to results
US 2007/0191315 A1Published application
Method for administering ibandronate
OwnerBengt Bergstrominventor
Life of this patent
Estimating the term…
Abstract
Disclosed is an improved method for treating pain associated with metastatic bone disease comprising the quick administration of an IV loading dose of ibandronate followed by an oral or intravenous (IV) maintenance dosing regimen. This method provides desirable therapeutic effects, including fast onset of pain relief, with a tolerable level of toxicity and is preferable for patient compliance.
Claims9
A method of treating the pain associated with metastatic bone disease in a subject in need thereof comprising the steps of:
- (a) intravenously administering a loading dose of ibandronate of about 4 mg to about 25 mg, over a loading period of from 1 to 3 days;
- then
- (b) orally administering a daily maintenance dose of ibandronate, the maintenance dose being administered commencing on from the 3rd to about the 30th day after commencement of the loading period.
A method for treating metastatic bone pain in a patient, comprising the steps of:
- (a) assessing the renal function of the patient to determine if the patient is suffering from mild to moderate renal impairment;
- and
- (b) if the patient has normal renal function, administering intravenously a loading dose of ibandronate of about 18 mg, in equal daily doses over a loading period of 3 consecutive days, followed by orally administering a 50 mg daily maintenance dose of ibandronate, administration of the maintenance dose starting 21 to 30 days after the first day of the loading period;
- and
- (c) if the patient is suffering from mild or moderate renal impairment, administering intravenously a loading dose of ibandronate of about 9 to about 12 mg, in equal daily doses over a loading period of 3 consecutive days, followed by orally administering a 50 mg daily maintenance dose of ibandronate, administration of the maintenance dose starting 21 to 30 days after the first day of the loading period
2 more elements
A method for treating metastatic bone pain in a patient, comprising the steps of:
- (a) assessing the renal function of the patient to determine if the patient is suffering from mild or moderate renal impairment;
- and
- (b) if the patient has normal renal function, administering intravenously a loading dose of ibandronate of about 18 mg, in equal daily doses over a loading period of 3 consecutive days, followed by orally administering a daily 50 mg maintenance dose of ibandronate, administration of the maintenance dose starting 21 to 30 days after the first day of the loading period;
- and
- (c) if the patient is suffering from mild renal impairment, administering intravenously a loading dose of ibandronate of about 12 mg, in equal daily doses over a loading period of 3 consecutive days, followed by orally administering a daily 50 mg maintenance dose of ibandronate, administration of the maintenance dose starting 21 to 30 days after the first day of the loading period;
- and
- (d) if the patient is suffering from moderate renal impairment, administering intravenously a loading dose of ibandronate of about 9 mg, in equal daily doses over a loading period of 3 consecutive days, followed by orally administering a 50 mg daily maintenance dose of ibandronate, administration of the maintenance dose starting 21 to 30 days after the first day of the loading period.
4 more elements
A method for treating metastatic bone pain in a patient, comprising the steps of:
- (a) assessing the renal function of the patient to determine if the patient is suffering from mild or moderate renal impairment;
- and
- (b) if the patient has normal renal function or is suffering from mild renal impairment, administering intravenously a loading dose of ibandronate of about 18 mg, in equal daily doses over a loading period of 3 consecutive days, followed by orally administering a daily maintenance dose of ibandronate, administration of the maintenance dose starting 21 to 30 days after the first day of the loading period;
- and
- (c) if the patient is suffering from moderate renal impairment, administering intravenously a loading dose of ibandronate of about 12 mg, in equal daily doses over a loading period of 3 consecutive days, followed by orally administering a daily maintenance dose of ibandronate, administration of the maintenance dose starting 21 to 30 days after the first day of the loading period.
2 more elements
Dependencies are inferred from the claim text.